Olema Pharmaceuticals (OLMA) surges after Roche's breast cancer data, but caution is urged as key clinical results are ...
Pharvaris advances an oral bradykinin B2 franchise with late-stage HAE programs, strong data, and major catalysts. Learn why ...
Inflammatory biomarkers in ischemic stroke: mechanisms, clinical applications, and future directions
Ischemic stroke is a complex cerebrovascular disorder characterized by highly unpredictable outcomes influenced by ...
At interim analysis, giredestrant demonstrated a statistically significant and clinically meaningful benefit versus ...
Ac-SSO110 has received U.S. FDA Orphan Drug Designation Initial safety data from SANTANA-225 in ES-SCLC and MCC expected in 2026 Potential to address a broad range of neuroendocrine cancers BERLIN, ...
Cellular death within the infarcted core occurs rapidly due to energy depletion, resulting in the release of DAMPs such as ...
The EMA’s recommendation follows evidence that the targeted therapy improves progression-free survival in patients whose ...
Updated MDNA11 Clinical Data from the ABILITY-1 Study will be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology ...
Ariceum Therapeutics begins patient dosing in in SANTANA-225 phase 1/2 trial of 225Ac-SSO110 to treat patients with ES-SCLC and Merkle cell carcinoma: Berlin, Germany Wednesday, N ...
MedPage Today on MSN
Benralizumab Cuts Hypereosinophilic Syndrome Flares
ORLANDO -- Anti-interleukin (IL)-5 receptor alpha monoclonal antibody benralizumab (Fasenra) reduced flares in ...
Data from the SERENITY At-Home Phase 3 trial were presented on November 7 at the 2025 Neuroscience Education Institute Fall Congress by Dr. Leslie Citrome.
Clinical Trials Arena on MSN
Synthekine reports initial STK-012 data in lung cancer trial
Synthekine has reported positive initial data from a Phase Ia/Ib trial evaluating STK-012 in first-line, programmed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback